Histopathologic Characteristics of Choroidal Melanoma in Eyes Enucleated After Iodine 125 Brachytherapy in the Collaborative Ocular Melanoma Study
Authors:
- Marie Diener-WestMDMarie Diener-West
- Sandra M. ReynoldsSRSandra M. Reynolds
- Hans E. GrossniklausHGHans E. Grossniklaus
- W. Richard GreenWGW. Richard Green
- Daniel M. AlbertDADaniel M. Albert
Open Access
- 1 February 2008
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of Ophthalmology (1950)
- Vol. 126 (2) , 207-212
Abstract
The Collaborative Ocular Melanoma Study (COMS) Group showed no difference in survival between patients randomized to primary enucleation compared with iodine 125 plaque brachytherapy.1,2 A potentially important subgroup of the radiotherapy arm are those patients who had secondary enucleation. Of the 650 COMS patients who received brachytherapy, the Kaplan-Meier estimate of secondary enucleation within 5 years of treatment was 12.5%.3 The clinical features of these “plaque failures” have been previously reported.3 Enucleations within the first 3 years after brachytherapy are likely due to treatment failure, and this is weakly associated with reduced survival after adjusting for other baseline variables (adjusted risk ratio, 1.5; 95% confidence interval, 0.94-2.52; P = .08).3 This study describes the histopathologic findings in eyes with failed plaques as compared with a control group with primary enucleation.Keywords
This publication has 1 reference indexed in Scilit:
- The COMS Randomized Trial of Iodine 125 Brachytherapy for Choroidal Melanoma, III: Initial Mortality FindingsArchives of Ophthalmology (1950), 2001